Upcoming Conferences for Iovance Biotherapeutics
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is gearing up for an exciting series of presentations at major health conferences. The company, known for its pioneering work in polyclonal tumor infiltrating lymphocyte (TIL) therapies, is set to showcase its innovations and advancements in cancer treatment. These conferences provide an excellent platform for the company to connect with industry leaders and share the impact of their cutting-edge therapies.
Wells Fargo Healthcare Conference
Fireside Chat Details
The first highlight is the participation in the 2025 Wells Fargo Healthcare Conference, where senior leadership will take part in a fireside chat scheduled for September 5, 2025, at 8:00 a.m. ET. This interactive session will delve into the latest developments within Iovance and the integral role of TIL therapies in revolutionizing cancer care.
H.C. Wainwright 27th Annual Global Investment Conference
Pivotal Presentation Scheduled
Another significant event on the agenda is the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 11:00 a.m. ET. This presentation aims to highlight Iovance's ongoing research efforts, recent clinical trial successes, and the company's strategic vision for future growth and innovation in cancer treatment.
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc. is dedicated to leading the way in TIL therapies. Their commitment lies in leveraging the human immune system to combat cancer effectively. With the Iovance TIL platform showcasing promising clinical outcomes across various solid tumors, the company aims for transformative breakthroughs in oncology. The FDA-approved Amtagvi is a significant milestone, marking a first in T cell therapies targeting solid tumors.
Commitment to Continuous Innovation
Iovance is consistently striving for innovation in cell therapy, exploring avenues like gene-edited cell therapy. Such advancements have the potential to significantly enhance patient outcomes and extend life expectancy in cancer treatment. The company’s relentless dedication to pushing the boundaries of science aims to provide hope where it is most needed.
Investor and Media Relations
For stakeholders interested in more information about the company, Iovance maintains open lines of communication. Investors can reach out to the dedicated Investor Relations team via email at IR@iovance.com or via phone at 650-260-7120 ext. 150. Media inquiries can be directed to PR@iovance.com with the same contact number for additional insights and media resources.
Frequently Asked Questions
What is Iovance Biotherapeutics known for?
Iovance Biotherapeutics specializes in developing TIL therapies to treat cancer, focusing on harnessing the body's immune system for healing.
When is Iovance presenting at the Wells Fargo Healthcare Conference?
The presentation at the Wells Fargo Healthcare Conference is scheduled for September 5, 2025, at 8:00 a.m. ET.
What innovations is Iovance focusing on?
Iovance is committed to continuous advancement in cell therapies, including exploring gene-edited cell therapy and other innovative treatments.
How can investors get in touch with Iovance?
Investors can contact Iovance’s Investor Relations team via email at IR@iovance.com.
What is the FDA-approved therapy by Iovance?
Amtagvi is the first FDA-approved therapy developed by Iovance Biotherapeutics targeting solid tumors, showcasing significant advancement in cancer treatment.
